PUBLIC HEALTHCARE CLINICS
SoftBank Group launches AI healthcare joint venture with Tempus AI
Anton Bridge reported SoftBank Group's collaboration with Tempus AI for medical data analysis, edited by Christopher Cushing and Miral Fahmy.
Nephro Care India IPO: Deepak Parekh-backed company to raise around Rs 40 crore via public issue on NSE Emerge
Deepak Parekh-backed multi-speciality healthcare provider Nephro Care India Limited (NCIL) is likely to raise around Rs 40 crore through the initial public offering (IPO) to fund its expansion plans.
JV Ventures forays into healthcare-dedicated infrastructure platform; plans to open 75 centres in next 5 years
JV Ventures diversifies into healthcare infrastructure with The Medical Centre (TMC), investing $600 million for 75 centers. Raja Jain appointed CEO. Vishal Goel and Jasmeet Singh Chhabra express optimism. TMC to offer specialized services in major Indian cities.
Responsible Innovation, how a blueprint for collaborative action is advancing global healthcare
On the occasion of the Abu Dhabi Global Healthcare Week (ADGHW), Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre, discusses the UAE's prioritisation of healthcare in driving investments and partnerships focusing on advancing technology and attracting top talent and fostering collaboration with India reflecting shared challenges and opportunities in healthcare. Overall, collaboration with global partners and investment in manufacturing capabilities exemplify the UAE's commitment to healthcare excellence and innovation, while initiatives like Malaffi enhance data-driven services. Read on to discover how ADGHW aims to faciliate responsible innovation in healthcare, even as the UAE emphasises patient rights protection in an era of advancing AI and data usage.
Defensive stocks: FMCG is “passe”; 8 stocks from two sectors may be called “new defensives” with upside potential of up to 32%
1994 to 2024 is a difference of 30 years, but there is one thing which has remained constant, advice to move to defensive stocks when markets are volatile or there is an event risk. Four questions need to be asked; first, what is a defensive stock? Second, is a stock which was considered a defensive in 1994 when the Indian economy was just opening, still a defensive stock in 2024 ? Third, should there be a new definition of defensive stock in 2024 ? Last but not the least, what are the new defensive sectors or stocks?
Empowering healthcare innovations: Dr. Noura Khamis Al Ghaithi on ADGHW's role in global healthcare collaboration
H.E. Dr. Noura Khamis Al Ghaithi discusses ADGHW as a platform for global healthcare collaboration, focusing on innovations and partnerships with Indian healthcare providers. The event aims to develop precision health initiatives, strengthen life sciences research, attract medical tourism, and support a growing startup ecosystem.
- Go To Page 1
Will short-term headwinds impact long-term potential? 6 stocks from hospital sector with upside potential of up to 30%
After outperforming the market, stocks from the healthcare sector or what is more commonly called hospital sector have gone into consolidation mode. The consolidation has been prompted by the fact that voices have been raised about differential pricing in the services of the hospitals. The matter has reached the Supreme Court and will be heard. Given the fact that while medicine is a science but in real life as practice it has an element of art in it. For example, a hospital who has a renowned surgeon from any branch, be it cardio, neuro on its roll may charge up more for the same surgery as compared to others. While the moral debate is on one side, there is another side to the story. In a country like India, the healthcare infrastructure needs vast expansion and upgradation. To some extent the street is ruthless and does not have much moral obligation.
Indegene IPO booked over 10x so far on Day 3. Check subscription, GMP and other details
Indegene IPO GMP: On the final day of the initial public offer (IPO), Indegene was booked a little over 10 times so far on Wednesday, the last day of the bidding process.
Indegene IPO booked over 4x so far on Day 2. Check subscription, GMP and other details
Indegene's IPO oversubscribed 4 times on the second day, led by non-institutional investors; QIB portion least subscribed.
Indegene IPO fully subscribed on Day 1. Check subscription, GMP and other details
On the first day of bidding, the initial public offering (IPO) of Indegene Ltd received a steady response, primarily fueled by strong interest from non-institutional investors (NII).
States seek more time for standard rates at hospitals
States, UTs, private hospitals seek more time for consultations on standard rates post Supreme Court directive. Court to hear plea by doctors, hospitals on government's rate prescription. Concerns raised on revenue impact. The order has led to widespread panic among private hospitals and investors, since standardisation of rates could substantially affect the revenue and commercial viability of hospital operations. Subsequently, healthcare providers wrote to the health ministry and the court, raising their concerns.
Hindujas sign new India-UK healthcare pact with King's College London
The Hinduja Group and King's College London partnership aims to enhance healthcare outcomes in India and the UK through training, research, and scholarships, creating the Hinduja-King's Health Partners Academy for future healthcare professionals.
Invest, and use market as medicine
The low investment in health has led to a demand-supply gap, which private sector has been closing. While this means choice, better medical services and more jobs, it has also led to anomalous pricing of procedures and high out-of-pocket expenditures, making implementation of a cashless health insurance system difficult.
Union ayush and health ministers to announce multi-centre clinical trial on anaemia
The Central Council for Research in Ayurvedic Sciences (CCRAS) and the Indian Council of Medical Research (ICMR) have launched a clinical trial to study the efficacy and safety of Punarnavadi Mandura, a polyherbal formulation rich in iron, in treating anemia among non-pregnant women of reproductive age. The trial will be conducted at eight sites, including MGIMS-Wardha, AIIMS-Jodhpur, NITM-Bengaluru, RIMS-Ranchi, KEM Hospital Research Centre, AIIMS-New Delhi, AIIMS-Bhopal, and AIIMS-Bibinagar.
Health risks for hospitals amid SC diktat, steep valuations
The Supreme Court's diktat comes as a negative surprise for the hospitals as their pricey valuations have triggered panic on D-Street as investors rushed to book profits in these counters. Hospital stocks were trading with deep cuts on Friday
SC pulls up Centre over rising disparity in pvt-govt medical expenses, says "act or we will implement CGHS rates"
The Supreme Court criticized the Indian government for the stark contrast in medical costs between public and private facilities, citing citizens' fundamental right to healthcare. The court urged the Centre to implement 14-year-old rules establishing standard rates for treatments in consultation with states. If a resolution isn't found, the court warned of considering the petitioner's plea to enforce CGHS-prescribed standardized rates.
Entero Healthcare Solutions shares list at 2% discount to IPO price
Entero Healthcare's IPO debuted with a discount on BSE and NSE. Proceeds will be used for debt repayment, working capital, funding subsidiaries, and inorganic growth. The company has 73 warehouses and supply relationships with over 1,900 healthcare product manufacturers. The target addressable market is valued at Rs 2.7 lakh crore.
Entero Healthcare shares to list on Friday. What GMP signals ahead of D-St debut
In the unlisted market, the company's shares are trading with a marginal premium of Rs 2, which indicates a flat or even a discounted debut at the bourses. The IPO comprised a fresh equity issue of Rs 1,000 crore and an offer for sale of up to 47.69 lakh shares.
Sharp companies leverage data to build out healthcare LLMs
Companies like Harman and Vizzhy leverage healthcare data to create large language models (LLMs) for hospitals. These LLMs automate hospital processes and help with clinical decision-making. VizzhyGPT is a multimodal model that understands text, images, audio, video, X-rays, and MRI scans.
Entero Healthcare IPO fully subscribed on final day. Check subscription, GMP and other details
Entero Healthcare IPO comprises a fresh equity issue of Rs 1,000 crore and an OFS of up to 47.69 lakh shares. Prabhat Agrawal, Prem Sethi, Orbimed Asia Iii Mauritius, Chethan MP, and Deepesh T Gala, among others, will offload shares under the OFS. The shares are trading with a marginal premium of Rs 10 in the grey market.
Entero Healthcare IPO sees tepid response. Check subscription, GMP, and other details
Entero Healthcare IPO price band has been fixed from Rs 1,195-1258 per equity share. Bids can be made for a minimum of 11 shares and in multiples thereafter. the shares are trading with a marginal premium of Rs 5 in the grey market.
Entero Healthcare IPO: Should you subscribe to this Rs 1600 crore issue?
Entero Healthcare recorded a 31% YoY increase in revenue from operations during FY23, reaching Rs 3,300 crore. ICICI Securities, Dam Capital Advisors, Jefferies India, JM Financial, and SBI Capital Markets are the book running lead managers for the IPO.
Entero Healthcare's Rs 1,600-cr IPO biggest so far in 2024: 10 things to know before subscribing to the issue
The IPO comprises a fresh equity issue of Rs 1,000 crore and an offer for sale of up to 47.69 lakh shares. Under the OFS, Prabhat Agrawal, Prem Sethi, Orbimed Asia Iii Mauritius, Chethan MP, Deepesh T Gala, among others, will offload shares.
Entero Healthcare announces dates, price band for its Rs 1,600-cr IPO
Entero Healthcare IPO: The price band has been fixed in the range of Rs 1,195-1,258 per equity share. Bids can be made for a minimum of 11 shares and in multiples thereafter. The IPO comprises a fresh equity issue of Rs 1,000 crore and an offer for sale of up to 47.69 lakh shares. Under the OFS, Prabhat Agrawal, Prem Sethi, Orbimed Asia Iii Mauritius, Chethan MP, Deepesh T Gala, among others, will offload shares.
Can't get enough of salty food? Potassium-rich alternatives to sodium, may help control high blood pressure
Switching to potassium-enriched salt is feasible in a way that cutting salt intake is not. Our new research concludes clinical guidelines for hypertension should give patients clear recommendations to switch.
France's Sanofi to buy US drugs project INBRX-101 for about $2.2 billion
French healthcare company Sanofi has agreed to buy drug development project INBRX-101 from parent company Inhibrx Inc for $2.2 billion. INBRX-101 is an experimental drug in clinical trials for treating Alpha-1 Antitrypsin Deficiency. Sanofi aims to boost its rare disease business with this acquisition. Inhibrx shareholders will receive cash, a contingent value right (CVR), and shares in New Inhibrx. Sanofi will assume third-party debts and fund New Inhibrx, while retaining an 8% equity interest.
Healthcare payments startup Waystar makes IPO filing public
Waystar confidentially filed for an IPO later in August, joining a wave of new listings that followed a months-long dry spell wrought by high interest rates and fears of a recession.
Watch how Volvo Car India is #PoweringLife in public healthcare clinics and biodiversity parks through sustainable giving
Volvo Cars is making strides towards sustainability by aiming to make 50% of its sales from electric models by 2025 and becoming a fully electric car company by 2030. The company is also working towards reducing emissions in its supply chain and operations. As an interim step, Volvo Cars aims to reduce the carbon footprint per vehicle by 40% between 2018 and 2025. Additionally, Volvo Car India has launched the #PoweringLife initiative, donating solar panels to hospitals and biodiversity parks in Delhi-NCR to reduce their carbon footprint and improve healthcare infrastructure.
Entero Healthcare files IPO papers with Sebi
The company proposes to utilise the net proceeds from the offer towards the repayment of certain borrowings, working capital requirements, for general corporate purposes and to pursue inorganic growth initiatives through acquisitions.
Load More
